{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:03:54Z","timestamp":1793754234350,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaad.2021.04.085","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T21:22:04Z","timestamp":1620076924000},"page":"863-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":297,"title":["Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies"],"prefix":"10.1016","volume":"85","author":[{"given":"Kim","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald Y.M.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May E.","family":"Venturanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Kuligowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2021.04.085_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient-burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.085_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/1346-8138.14116","article-title":"Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis","volume":"45","author":"Wei","year":"2018","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.085_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pedhc.2017.10.002","article-title":"Pathophysiology and management of mild to moderate pediatric atopic dermatitis","volume":"32","author":"Sayaseng","year":"2018","journal-title":"J Pediatr Health Care"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.085_bib4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.085_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.085_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-4362.2002.01436.x","article-title":"Atopic dermatitis is associated with a decrement in health-related quality of life","volume":"41","author":"Kiebert","year":"2002","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.085_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.04.085_bib8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jdv.13689","article-title":"Quality of life and disease severity in patients with atopic dermatitis","volume":"30","author":"Holm","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.085_bib9","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1080\/03007995.2018.1498329","article-title":"Patient impact and economic burden of mild-to-moderate atopic dermatitis","volume":"34","author":"Hebert","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.085_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.085_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2340\/00015555-3065","article-title":"Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis","volume":"99","author":"Kaaz","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.085_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.085_bib13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaci.2009.03.032","article-title":"Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis","volume":"123","author":"Jensen","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2021.04.085_bib14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000446068","article-title":"Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study","volume":"232","author":"Muller","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2021.04.085_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2011.10449.x","article-title":"Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency","volume":"165","author":"Aubert-Wastiaux","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.085_bib16","first-page":"e24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.085_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.085_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"120","author":"Howell","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"15","key":"10.1016\/j.jaad.2021.04.085_bib19","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.085_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.085_bib21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.085_bib22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/sleep\/33.6.781","article-title":"Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments","volume":"33","author":"Buysse","year":"2010","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.jaad.2021.04.085_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clindermatol.2017.03.008","article-title":"Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders","volume":"35","author":"Silverberg","year":"2017","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.085_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.085_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.085_bib26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis","volume":"177","author":"Chopra","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.04.085_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.16078","article-title":"Severity strata for five patient-reported outcomes in adults with atopic dermatitis","volume":"178","author":"Vakharia","year":"2018","journal-title":"Br J Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2021.04.085_bib28","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1177\/1203475418803628","article-title":"Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis","volume":"22","author":"Gooderham","year":"2018","journal-title":"J Cutan Med Surg"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221009312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221009312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:37Z","timestamp":1759273297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221009312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0190962221009312"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}